Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease

CD Fisher, AJ Lickteig, LM Augustine… - Drug metabolism and …, 2009 - ASPET
Members of the cytochrome P450 (P450) enzyme families CYP1, CYP2, and CYP3 are
responsible for the metabolism of approximately 75% of all clinically relevant drugs. With the …

Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats

CD Fisher, AJ Lickteig, LM Augustine… - European journal of …, 2009 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of diagnoses ranging
from simple fatty liver (SFL), to non-alcoholic steatohepatitis (NASH). This study aimed to …

Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease

AJ Lickteig, CD Fisher, LM Augustine… - Drug metabolism and …, 2007 - ASPET
Efflux transporters are responsible for the excretion of numerous xenobiotics and endobiotics
and thus play an essential role in proper liver and kidney function. Nonalcoholic fatty liver …

Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice

AJ Lickteig, X Cheng, LM Augustine, CD Klaassen… - Life sciences, 2008 - Elsevier
Transporters are expressed in a wide variety of tissues where they perform the critical function
of enabling anionic and cationic chemicals of exogenous and endogenous origin to cross …

Synergistic interaction between genetics and disease on pravastatin disposition

JD Clarke, RN Hardwick, AD Lake, AJ Lickteig… - Journal of …, 2014 - Elsevier
Background & Aims A genome wide association study and multiple pharmacogenetic studies
have implicated the hepatic uptake transporter organic anion transporting polypeptide-1B1 …

Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis

CD Fisher, JP Jackson, AJ Lickteig, LM Augustine… - Archives of …, 2008 - Springer
Non-alcoholic steatohepatitis (NASH) is a disease that compromises hepatic function and
the capacity to metabolize numerous drugs. Aryl hydrocarbon receptor (AhR), constitutive …

Tissue distribution, ontogeny, and chemical induction of aldo-keto reductases in mice

M Pratt-Hyatt, AJ Lickteig, CD Klaassen - Drug Metabolism and Disposition, 2013 - ASPET
Aldo-keto reductases (Akrs) are a conserved group of NADPH-dependent oxido-reductase
enzymes. This study provides a comprehensive examination of the tissue distribution of the …

Editor's highlight: Clofibrate decreases bile acids in livers of male mice by increasing biliary bile acid excretion in a PPARα-dependent manner

Y Zhang, AJ Lickteig, IL Csanaky… - Toxicological …, 2017 - academic.oup.com
… Andrew J Lickteig , Andrew J Lickteig … Youcai Zhang, Andrew J Lickteig, Iván L Csanaky,
Curtis D Klaassen, Editor’s Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by …

Differential regulation of hepatic transporters in the absence of tumor necrosis factor-α, interleukin-1β, interleukin-6, and nuclear factor-κB in two models of cholestasis

AJ Lickteig, AL Slitt, MC Arkan, M Karin… - Drug metabolism and …, 2007 - ASPET
Hepatic transporters are responsible for uptake and efflux of bile acids and xenobiotics as an
essential aspect of liver function. When normal vectorial transport of bile acids by the apical …

Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis

AJ Lickteig, CD Fisher, LM Augustine… - … of biochemical and …, 2007 - Wiley Online Library
Nonalcoholic fatty liver disease encompasses a spectrum of hepatic pathologies ranging
from simple fatty liver to an inflammatory state known as nonalcoholic steatohepatitis (NASH). …